ReviewCureus2025
PulseRider Aneurysm Neck Reconstructive Device Versus Other Treatments in Patients With Wide-Neck Bifurcation Aneurysms: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wide-neck bifurcation aneurysms (WNBA) are challenging to treat both surgically and endovascularly due to their complex anatomy. The FDA-approved PulseRider Aneurysm Neck Reconstructive Device (PRANRD; Cerenovus, Johnson & Johnson, Irvine, CA, USA) offers a novel endovascular treatment option; however, comparative data on its safety and efficacy remain limited. This review compares PRANRD with other treatment modalities for unruptured WNBA. A search of multiple databases identified 51 articles, of which three met the inclusion criteria, comprising two cohort studies and one case series, for a total of 134 patients treated with PRANRD. The device achieved complete angiographic occlusion in most cases with low complication rates. Compared to Y-stenting, PRANRD-assisted coiling demonstrated similar immediate occlusion rates but lower complete occlusion rates at six months. No procedure-related mortality was reported. However, long-term follow-up and randomized controlled trials are still required. PRANRD appears to be a promising alternative for treating WNBA, offering high occlusion rates and a favorable safety profile. Further research is necessary to confirm its long-term efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.